Login
$RLMD
$3.61 +$0.00 (0.0%) After hours

$RLMD 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure

Date of Report (Date of earliest event reported): November 16, 2026

12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

08 Sep 2026 8-K: Other Events

Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026.

06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.

28 Jul 2026 8-K: Regulation FD Disclosure

Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation.

28 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Name of entity as on file with the Nevada Secretary of State : RELMADA THERAPEUTICS, INC. Entity or Nevada Business Identification Number (NVID) : NV20121345551 1. Entity information Certificate to Accompany Restated Articles or Amended ...

12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a dura...

20 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile

09 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 9, 2026, by and among Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (e...

15 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your crede...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

05 Nov 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Introductory. Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 40,142,000 shares of its common stock, pa...

04 Nov 2025 8-K: Regulation FD Disclosure; Other Events

Unlocking Life Changing Therapies October 2025 C O R PO R AT E O VER VI E W

17 Sep 2025 8-K: Regulation FD Disclosure

Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W

16 Sep 2025 8-K: Other Events

CORAL GABLES, FL – September 16, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous...

10 Sep 2025 8-K: Regulation FD Disclosure

Unlocking Life Changing Therapies August 2025 C O R PO R AT E O VER VI E W

02 Sep 2025 8-K: Regulation FD Disclosure

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the “Company”), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share.

07 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

23 Jul 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the...

10 Jul 2025 8-K: Termination of a Material Definitive Agreement

In January 2018, Relmada Therapeutics, Inc. (“Relmada,” the “Company,” “we,” “us,” “our”) entered into a License Agreement (the “License Agreement”) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursu...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support